[Focus] Sales policy of new Sanofi-Aventis company attracts keen interest

Published: 2004-08-17 06:59:00

Updated: 2004-08-17 06:59:00

As Sanofi-Synthelabo and Aventis SA plans to create the world' third largest pharmaceutical company on August 20 after Sanofi increased an earlier hostile bid for Aventis, domestic drug wholesalers and pharmaceutical firms have been closely watching the movement of Sanofi Korea, notably on their ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK